

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

· APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/686,647	10/10/2000	Jeffrey M. Friedman	600-1-087CIP/DIV/COM	6790	
75	590 08/28/2003				
David A Jackson Esq			EXAM	EXAMINER	
Klauber & Jack 411 Hackensach	k Avenue		MARVICH	i, MARIA	
Hackensack, NJ 07601			ART UNIT	PAPER NUMBER	
			1636	18	
			DATE MAILED: 08/28/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/686,647	FRIEDMAN ET AL.				
	Office Action Summary	Examiner	Art Unit				
-		Maria B Marvich, F					
Th MAILING DATE of this communication appears on the cover she t with th correspond nce address							
Period for Reply							
THE - Exte after - If the - If NO - Failt - Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we use to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing end patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however within the statutory minim rill apply and will expire SI cause the application to b	or, may a reply be timely filed  um of thirty (30) days will be considered timely.  ( (6) MONTHS from the mailing date of this communication. ecome ABANDONED (35 U.S.C. § 133).				
1) 🖂	Responsive to communication(s) filed on 30 J	ulv 2003					
2a) □		s action is non-fina	al.				
3)⊠	<i>,</i> —						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>							
4)⊠ Claim(s) <u>59-65</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)⊠	)⊠ Claim(s) <u>59-65</u> is/are allowed.						
6)	6) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.							
	ion Papers						
·	The specification is objected to by the Examiner		_				
10)⊠	The drawing(s) filed on <u>06 February 2003</u> is/are						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.						
2. Certified copies of the priority documents have been received in Application No							
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>							
Attachment(s)							
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 N	nterview Summary (PTO-413) Paper No(s). <u>18</u> lotice of Informal Patent Application (PTO-152) ther:				

Application/Control Number: 09/686,647

Art Unit: 1636

## **DETAILED ACTION**

This office action is in response to an amendment filed 7/30/03. Claims 59-65 are pending in this application. Terminal Disclaimers to Obviate a Double Patenting Rejection over US Patent No. 6,471,956 and 6,429,290 have been filed.

This application is in condition for allowance except for the following formal matters:

## Specification

Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows:

An application in which the benefits of an earlier application are desired must contain a specific reference to the prior application(s) in the first sentence of the specification of in an application data sheet (37 CFR 1.78(a)(2) and (a)(5)). The specific reference to any prior nonprovisional application must include the relationship (i.e., continuation, divisional, or continuation-in-part) between the applications except when the reference is to a prior application of a CPA assigned the same application number. In the instant application the reference to the prior application is in the 7<sup>th</sup> line and the continuing data does not reference all of the prior applications.

Application/Control No

Art Unit: 1636

Oath/Declaration

The oath or declaration is defective. A new oath or declaration in compliance with 37

CFR 1.67(a) identifying this application by application number and filing date is required. See

MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

Non-initialed and/or non-dated alterations have been made to the oath or declaration. See

37 CFR 1.52(c).

Sequence Compliance

This application contains sequence disclosures that are encompassed by the definitions

for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However,

this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the

reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent

Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Specifically, there is an amino acid sequence in Figure 14.

Prosecution on the merits is closed in accordance with the practice under Ex parte

Quayle, 1935 C.D. 11, 453 O.G. 213.

A shortened statutory period for reply to this action is set to expire TWO MONTHS

from the mailing date of this letter.

Conclusion

Claims 59-65 are allowed.

Application/Control Number: 09/686,647

Art Unit: 1636

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria B Marvich, PhD whose telephone number is (703) 605-1207. The examiner can normally be reached on M-F (6:30-3:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, PhD can be reached on (703) 305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 305-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

> Maria B Marvich, PhD Examiner Art Unit 1636

August 26, 2003

Page 4